Bragar Eagel & Squire, P.C. is Investigating DBV Technologies S.A. (DBVT) on Behalf of Stockholders and Encourages DBVT Investors to Contact the Firm
NEW YORK, Dec. 28, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against DBV Technologies S.A. (NASDAQ: DBVT). Our investigation concerns whether DBV has violated the federal securities laws and/or engaged in other unlawful business practices.
On December 19, 2018, DBV revealed that following discussions with the U.S. Food and Drug Administration (“FDA”), its Biologics License Application (“BLA”) for Viaskin Peanut in children four to eleven years of age has been voluntarily withdrawn. The company stated, “although the agency did not reference any medical or clinical questions with the submission of Viaskin Peanut, the FDA did communicate that the level of detail with regards to data on manufacturing and quality controls was insufficient in the BLA.”
On this news, DBV’s share price fell by nearly 60%, closing at $5.76 per share on December 20, 2018.
If you purchased or otherwise acquired DBV shares and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into DBV please go to http://www.bespc.com/dbvt/. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.